Form 25-NSE Viking Therapeutics, Filed by: Nasdaq Stock Market LLC

    X0203

    
        0001354457
        Nasdaq Stock Market LLC
    

    
        0001607678
        Viking Therapeutics, Inc.
        001-37355
        

            11119 North Torrey Pines Road, Suite 50
            
            San Diego
            CA
            CALIFORNIA
            92037
        
        858-550-7810
    

    Viking Therapeutics, Inc. Warrants expiring 04/13/2021

    17 CFR 240.12d2-2(a)(2)

    
        Tara Petta
        Director
        2021-04-08
    

form25

You May Also Be Interested In

• Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
• Ageas and Fosun: Transparency notification
• Forsee Power's 2023 Annual Results: Strong Commercial and Financial Performance